Author

L. Chesler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:drug response / drug discovery· 5 Organism:human· 5 Research Focus:cell type annotation· 4 Organism:mouse· 4 Assay:bulk RNA-seq· 3 Research Focus:cell signaling & trafficking· 2 Research Focus:differential expression· 2

Frequent Co-Authors

E. Poon· 6 shared Y. Jamin· 3 shared B. Geoerger· 2 shared B. Martins da Costa· 2 shared F. van den Ham· 2 shared G. Schleiermacher· 2 shared H. Che· 2 shared J. Anderson· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersCancer Biology

E. Poon

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Glutamine addiction is targetable via altering splicing of nutrient sensors and epitranscriptome regulators

J. Bojko, M. Kollareddy, M. Szemes, J. Bellamy, E. Poon, A. Moukachar, D. Legge, E. E. Vincent, N. Jones, S. Malik, A. Greenhough, A. Paterson, J. H. Park, K. Gallacher, L. Chesler, K. Malik

This study shows PRMT5 inhibition targets MNA neuroblastoma by altering splicing of nutrient sensors and epitranscriptome regulators, leading to growth inhibition and apoptosis.

bioRxiv · Feb 28, 2024 · PreprintCancer Biology

Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function

M. Barisa, E. Zappa, H. Muller, R. Shah, J. Buhl, B. Draper, C. Himsworth, C. Bowers, S. Munnings-Tomes, M. Nicolaidou, S. Morlando, K. Birley, C. Leboreiro-Babe, A. Vitali, L. Privitera, , J. Anderson

The paper evaluates how the functional avidity of anti-B7H3 CAR-T constructs relates to their ability to trigger effector function against tumors with varying antigen density.

bioRxiv · Feb 19, 2024Bioengineering

Environment-Dependent Modes of Adaptive Evolution in Neuroblastoma: Plasticity as a Selectable Trait

C. Roux, S. Hamer, A. Shea, E. Chen, A. S. Sadr, C. English, A. Allo Anido, H. Che, B. Geoerger, L. Chesler, G. Schleiermacher, M. D. Morgan, A. Bruna

This study identifies three modes of plasticity in neuroblastoma that shape tumour evolution under selective pressures and therapy resistance.

bioRxiv · Dec 7, 2023 · PreprintCancer Biology

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELS.

E. Tucker, I. Jimenez, L. Chen, A. Bellini, C. Gorrini, E. Calton, Q. Gao, H. Che, E. Poon, Y. Jamin, B. Martins da Costa, K. Barker, S. Shrestha, C. Hutchinson, S. Dhariwal, , G. Schleiermacher

This study evaluates lorlatinib, an ALK inhibitor, in combination with chemotherapy or idasanutlin in preclinical neuroblastoma models, finding synergy in models with high ALK expression.

Clinical Cancer Research · Apr 3, 2023Peer-reviewedCancer Biology

A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations

I. M. Saldana-Guerrero, L. F. Montano-Gutierrez, K. Boswell, C. Hafemeister, E. Poon, L. E. Shaw, D. Stavish, R. A. Lea, S. Wernig-Zorc, E. Bozsaky, I. S. Fetahu, P. Zoescher, U. Pötschger, M. Bernkopf, A. Wenninger-Weinzierl, , F. Halbritter

The paper uses human embryonic stem cells to show that chromosomal gains in neuroblastoma impair neural crest development and enhance MYCN-driven tumourigenesis.

bioRxiv · Nov 21, 2022Cancer Biology

Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

J. Wienke, L. L. Visser, W. M. Kholosy, K. M. Keller, M. Barisa, S. Munnings-Tomes, E. Carlton, E. Poon, A. Rodriguez, R. Bernardi, F. Van den Ham, S. R. Van Hooff, Y. A. H. Matser, M. Tas, K. P. S. Langenberg, , J. J Molenaar

The paper uses single-cell RNA sequencing to analyze neuroblastoma and identifies the NECTIN2-TIGIT axis as a potential target for immunotherapy.

bioRxiv · Jul 15, 2022Cancer Biology

Indisulam targets RNA splicing and metabolism to serve as a novel therapeutic strategy for high-risk neuroblastoma

A. Nijhuis, A. Sikka, O. Yogev, L. Herendi, C. Eckold, G. Valbuena, Y. Liu, E. Kouloura, E. Poon, B. Martins da Costa, A. Benito, H. Kramer, A. Montoya, D. Carling, E. J. Want, , H. C. Keun

This study shows that indisulam, a sulphonamide, targets RNA splicing and metabolism to inhibit neuroblastoma growth and achieve complete tumor remission in preclinical models.

bioRxiv · Dec 18, 2020Cancer Biology

Sulfopin, a selective covalent inhibitor of Pin1, blocks Myc-driven tumor initiation and growth in vivo

C. Dubiella, B. J. Pinch, D. Zaidman, T. D. Manz, E. Poon, S. He, E. Resnick, E. M. Langer, C. J. Daniel, H.-S. Seo, Y. Chen, S. B. Ficarro, Y. Jamin, X. Lian, S. Kibe, , N. London

Sulfopin, a selective Pin1 inhibitor, reduces tumor initiation and growth in neuroblastoma models by targeting c-Myc pathways.

bioRxiv · Mar 20, 2020 · PreprintCancer Biology